Cannabinoids Clinical Trials Conditions Packaging 
Cannabis Law Report
OCTOBER 6, 2021
Flora Pharma’s objective is to create and leverage a proprietary drug development platform in collaboration with an artificial intelligence and machine learning group to identify new bioactive compounds within the cannabis plant that interact with certain gene targets responsible for specific disease states and conditions.
Cannabis Law Report
SEPTEMBER 14, 2021
A lack of consumer trust, transparency and scientific rigor has hampered the CBD and cannabinoid industry from reaching its growth potential for far too long”. Step four: Brands select packaging, labels and other physical concepts for the selected product in a fully customizable experience.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
SEPTEMBER 8, 2021
The Company provides proprietary cannabis processing services, in addition to best-in-class product development, manufacturing, and commercialization of cannabis consumer packaged goods. The conditions precedent for the execution of the Definitive Agreements are: a. . Schedule 1. the “Operational Agreement”); and.
Puff Puff Post
NOVEMBER 5, 2019
. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.
Cannabis Law Report
APRIL 10, 2019
In November, UK law changed to allow clinicians to prescribe medical cannabis under limited conditions. To date, research has centred on two major cannabinoids, tetrahydrocannabinol and cannabidiol. Here’s a quick precis care of Cannabis Wire Daily Newswire. This is a very difficult area, with some heart-rending cases.
Puff Puff Post
NOVEMBER 5, 2019
. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.
Cannabis Law Report
JANUARY 9, 2019
Phoenix, headquartered in Denver, distributes medicinal cannabis products around the globe to treat seven major categories of medical conditions including pain, cancer, autoimmune, metabolic, neurological, psychological and sleep disorders. Tindall also hope to commence the clinical trials with Vanuatu for diabetes treatment.
Expert insights. Personalized for you.
52 
Let's personalize your content